M. Aas, P. Dazzan, V. Mondelli, I. Melle, R. M. Murray et al., A systematic review of cognitive function in first-episode psychosis, including a discussion on childhood trauma, stress, and inflammation. Front, Psychiatry, vol.4, 2014.

J. Agnew-blais and L. J. Seidman, Neurocognition in youth and young adults under age 30 at familial risk for schizophrenia: a quantitative and qualitative review, Cognit. Neuropsychiatry, vol.18, pp.44-82, 2013.

A. Anticevic, M. Gancsos, J. D. Murray, G. Repovs, N. R. Driesen et al., NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia, Proc. Natl. Acad. Sci. U. S. A, vol.109, pp.16720-16725, 2012.

A. S. Bassett, C. Lowther, D. Merico, G. Costain, E. W. Chow et al., Rare Genome-Wide Copy Number Variation and Expression of Schizophrenia in 22q11.2 Deletion Syndrome, International 22q11.2DS Brain and Behavior Consortium, 2017.

J. A. Bodkin, M. J. Coleman, L. J. Godfrey, C. M. Carvalho, C. J. Morgan et al., Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene, Biol. Psychiatry, vol.86, pp.523-535, 2019.

E. Bora and R. M. Murray, Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis?, Schizophr. Bull, vol.40, pp.744-755, 2014.

W. J. Brewer, S. J. Wood, L. J. Phillips, S. M. Francey, C. Pantelis et al., Generalized and Specific Cognitive Performance in Clinical High-Risk Cohorts: A Review Highlighting Potential Vulnerability Markers for Psychosis, Schizophr. Bull, vol.32, pp.538-555, 2006.

L. Buchy, L. J. Seidman, K. S. Cadenhead, T. D. Cannon, B. A. Cornblatt et al., Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis, Psychiatry Res, vol.230, pp.878-884, 2015.

R. E. Carrión, D. J. Walder, A. M. Auther, D. Mclaughlin, H. O. Zyla et al., From the psychosis prodrome to the firstepisode of psychosis: No evidence of a cognitive decline, J. Psychiatr. Res, vol.96, pp.231-238, 2018.

P. W. Chiu, S. S. Lui, K. S. Hung, R. C. Chan, Q. Chan et al., In vivo gamma-aminobutyric acid and glutamate levels in people with firstepisode schizophrenia: A proton magnetic resonance spectroscopy study, Schizophr. Res, 2017.

K. H. Choi, M. E. Zepp, B. W. Higgs, C. S. Weickert, and M. J. Webster, Expression profiles of schizophrenia susceptibility genes during human prefrontal cortical development, J. Psychiatry Neurosci. JPN, vol.34, pp.450-458, 2009.

C. I. Cohen and T. Murante, A prospective analysis of the role of cognition in three models of aging and schizophrenia, Schizophr. Res, 2017.

J. Elia, J. T. Glessner, K. Wang, N. Takahashi, C. J. Shtir et al., Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder, Nat. Genet, vol.44, pp.78-84, 2011.

P. Fusar-poli, G. Deste, R. Smieskova, S. Barlati, A. R. Yung et al., Cognitive functioning in prodromal psychosis: a metaanalysis, Arch. Gen. Psychiatry, vol.69, pp.562-571, 2012.

N. Grau, E. Rubio-abadal, J. Usall, A. Barajas, A. Butjosa et al., Influence of cognition, premorbid adjustment and psychotic symptoms on psycho-social functioning in first-episode psychosis, Psychiatry Res, vol.242, pp.157-162, 2016.

M. F. Green and P. D. Harvey, Cognition in schizophrenia: Past, present, and future, Schizophr. Res. Cogn, vol.1, pp.1-9, 2014.

A. P. Hulkko, G. K. Murray, J. Moilanen, M. Haapea, I. Rannikko et al., Lifetime use of psychiatric medications and cognition at 43years of age in schizophrenia in the Northern Finland Birth Cohort, Eur. Psychiatry, vol.45, pp.50-58, 1966.

A. P. Husa, I. Rannikko, J. Moilanen, M. Haapea, G. K. Murray et al., Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia -An observational 9-year follow-up study, Schizophr. Res, vol.158, pp.134-141, 2014.

Y. Iwata, S. Nakajima, T. Suzuki, R. Keefe, E. Plitman et al., Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of doubleblind randomized controlled trials, Mol. Psychiatry, vol.20, pp.1151-1160, 2015.

S. Iyer, G. Jordan, K. Macdonald, R. Joober, and A. Malla, Early intervention for psychosis: a Canadian perspective, J. Nerv. Ment. Dis, vol.203, pp.356-364, 2015.

R. S. Kahn, I. E. Sommer, R. M. Murray, A. Meyer-lindenberg, D. R. Weinberger et al., Nat. Rev. Dis. Primer, vol.15067, 2015.

R. Kandaswamy, A. Mcquillin, D. Curtis, and H. Gurling, Allelic association, DNA resequencing and copy number variation at the metabotropic glutamate receptor GRM7 gene locus in bipolar disorder, Am. J. Med. Genet. Part B Neuropsychiatr. Genet. Off. Publ. Int. Soc. Psychiatr. Genet, vol.165, pp.365-372, 2014.

J. T. Kantrowitz, A. K. Malhotra, B. Cornblatt, G. Silipo, A. Balla et al., High dose D-serine in the treatment of schizophrenia, Schizophr. Res, vol.121, pp.125-130, 2010.

J. T. Kantrowitz, S. W. Woods, E. Petkova, B. Cornblatt, C. M. Corcoran et al., D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial, Lancet Psychiatry, vol.2, pp.403-412, 2015.

G. M. Khandaker, J. H. Barnett, I. R. White, and P. B. Jones, A quantitative meta-analysis of population-based studies of premorbid intelligence and schizophrenia, Schizophr. Res, vol.132, pp.220-227, 2011.

S. Kim, M. J. Kaufman, B. M. Cohen, J. E. Jensen, J. T. Coyle et al., In Vivo Brain Glycine and Glutamate Concentrations in Patients With First-Episode Psychosis Measured by Echo Time-Averaged Proton Magnetic Resonance Spectroscopy at 4T, Biol. Psychiatry, 2017.

M. Krebs, E. Magaud, D. Willard, C. Elkhazen, F. Chauchot et al., , 2014.

, , vol.40, pp.447-456

E. Leiderman, I. Zylberman, S. R. Zukin, T. B. Cooper, and D. C. Javitt, Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial, Biol. Psychiatry, vol.39, pp.585-589, 1996.

T. Lencz, E. Knowles, G. Davies, S. Guha, D. C. Liewald et al., Molecular genetic evidence for overlap between general cognitive ability and risk for schizophrenia: a report from the, Cognitive Genomics consorTium (COGENT). Mol. Psychiatry, vol.19, pp.168-174, 2014.

W. Li, K. Ju, Z. Li, K. He, J. Chen et al., Significant association of GRM7 and GRM8 genes with schizophrenia and major depressive disorder in the Han Chinese population, Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol, vol.26, pp.136-146, 2016.

W. Liang, H. Yu, Y. Su, T. Lu, H. Yan et al., Variants of GRM7 as risk factor and response to antipsychotic therapy in schizophrenia, Transl. Psychiatry, vol.10, 2020.

Y. Liu, Y. Zhang, D. Zhao, R. Dong, X. Yang et al., Rare de novo deletion of metabotropic glutamate receptor 7 (GRM7) gene in a patient with autism spectrum disorder, Am. J. Med. Genet. Part B Neuropsychiatr. Genet. Off. Publ. Int. Soc. Psychiatr. Genet, vol.168, pp.258-264, 2015.

E. Magaud, Y. Morvan, A. Rampazzo, C. Alexandre, D. Willard et al., Subjects at Ultra High Risk for psychosis have "heterogeneous" intellectual functioning profile: a multiple-case study, Schizophr. Res, vol.152, pp.415-420, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01312814

C. Mam-lam-fook, C. Danset-alexandre, L. Pedron, I. Amado, R. Gaillard et al., Neuropsychology of subjects with ultra-high risk (UHR) of psychosis: A critical analysis of the literature, L'Encephale, vol.43, pp.241-253, 2017.

N. Matosin and K. A. Newell, Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia, Neurosci. Biobehav. Rev, vol.37, pp.256-268, 2013.

K. Merritt, A. Egerton, M. J. Kempton, M. J. Taylor, and P. K. Mcguire, Nature of Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies, JAMA Psychiatry, vol.73, pp.665-674, 2016.

M. J. Millan, A. Andrieux, G. Bartzokis, K. Cadenhead, P. Dazzan et al., Altering the course of schizophrenia: progress and perspectives, Nat. Rev. Drug Discov, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01936376

K. H. Nuechterlein, J. Ventura, K. L. Subotnik, and G. Bartzokis, The early longitudinal course of cognitive deficits in schizophrenia, J. Clin. Psychiatry, vol.75, issue.2, pp.25-29, 2014.

A. Oppetit, J. Bourgin, G. Martinez, M. Kazes, C. Mam-lam-fook et al., The C'JAAD: a French team for early intervention in psychosis in Paris, Early Interv. Psychiatry, 2016.

M. J. Owen, A. Sawa, and P. B. Mortensen, Lancet Lond. Engl, vol.388, pp.1121-1127, 2016.

E. Plitman, C. De-la-fuente-sandoval, F. Reyes-madrigal, S. Chavez, G. Gómez-cruz et al., Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction, Schizophr. Bull, vol.42, pp.415-424, 2016.

R. Plomin, S. Stumm, and . Von, The new genetics of intelligence, Nat. Rev. Genet, vol.19, pp.148-159, 2018.

M. S. Reuter, H. Tawamie, R. Buchert, O. Hosny-gebril, T. Froukh et al., Diagnostic Yield and Novel Candidate Genes by Exome Sequencing in 152 Consanguineous Families With Neurodevelopmental Disorders, JAMA Psychiatry, vol.74, pp.293-299, 2017.

E. Sacchetti, C. Magri, A. Minelli, P. Valsecchi, M. Traversa et al., The GRM7 gene, early response to risperidone, and schizophrenia: a genomewide association study and a confirmatory pharmacogenetic analysis, Pharmacogenomics J, vol.17, pp.146-154, 2017.

N. G. Skene, J. Bryois, T. E. Bakken, G. Breen, J. J. Crowley et al., Genetic identification of brain cell types underlying schizophrenia, Nat. Genet, vol.50, pp.825-833, 2018.

O. B. Smeland, O. Frei, K. Kauppi, W. D. Hill, W. Li et al., NeuroCHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology

, Identification of Genetic Loci Jointly Influencing Schizophrenia Risk and the Cognitive Traits of Verbal-Numerical Reasoning, Reaction Time, and General Cognitive Function, JAMA Psychiatry, 2017.

S. Sniekers, S. Stringer, K. Watanabe, P. R. Jansen, J. R. Coleman et al., Genome-wide association meta-analysis of 78,308 individuals identifies new loci and genes influencing human intelligence, Nat. Genet, vol.49, pp.1107-1112, 2017.

M. Spangaro, M. Bosia, M. Bechi, M. Buonocore, F. Cocchi et al., Neurobiology of cognitive remediation in schizophrenia: Effects of EAAT2 polymorphism, Schizophr. Res, vol.202, pp.106-110, 2018.

M. Spangaro, M. Bosia, A. Zanoletti, M. Bechi, B. Mariachiara et al., Exploring effects of EAAT polymorphisms on cognitive functions in schizophrenia, Pharmacogenomics, vol.15, pp.925-932, 2014.

J. M. Stevenson, J. L. Reilly, M. S. Harris, S. R. Patel, P. J. Weiden et al., Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes, Transl. Psychiatry, vol.6, 2016.

J. Tarabeux, O. Kebir, J. Gauthier, F. F. Hamdan, L. Xiong et al., Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia, Transl. Psychiatry, vol.1, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01133889

E. H. Thomas, K. Bozaoglu, S. L. Rossell, and C. Gurvich, The influence of the glutamatergic system on cognition in schizophrenia: A systematic review, Neurosci. Biobehav. Rev, vol.77, pp.369-387, 2017.

T. Toulopoulou, M. Picchioni, F. Rijsdijk, M. Hua-hall, U. Ettinger et al., Substantial genetic overlap between neurocognition and schizophrenia: genetic modeling in twin samples, Arch. Gen. Psychiatry, vol.64, pp.1348-1355, 2007.

F. Vinckier, R. Gaillard, S. Palminteri, L. Rigoux, A. Salvador et al., Confidence and psychosis: a neurocomputational account of contingency learning disruption by NMDA blockade, Mol. Psychiatry, vol.21, pp.946-955, 2016.

, Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls, Nature, vol.447, pp.661-678, 2007.

W. Xia, Y. Liu, and J. Jiao, GRM7 Regulates Embryonic Neurogenesis via CREB and YAP. Stem Cell Rep, vol.4, pp.795-810, 2015.

G. Zai, T. W. Robbins, B. J. Sahakian, and J. L. Kennedy, A review of molecular genetic studies of neurocognitive deficits in schizophrenia, Neurosci. Biobehav. Rev, vol.72, pp.50-67, 2017.

W. Zhang, E. R. Gamazon, X. Zhang, A. Konkashbaev, C. Liu et al., SCAN database: facilitating integrative analyses of cytosine modification and expression QTL, Database J. Biol. Databases Curation, 2015.